
Scanlan vows 'unprecedented transparency' with pooled risk receiver
At Scanlan's urging, Merrimack County Superior Court Judge Martin Honigberg last month named Lance Turgeon, a financial executive with Wipfli LLP, as receiver, to make all decisions regarding New Hampshire Interlocal Trust (NHIT) finances.
'It's a borderline situation right now,' Turgeon told reporters at a news conference Scanlan called in his office Tuesday.
'Look at the cash position of the trust, it's a negative number and the known claims, that is a negative number too.'
Christina Ferrari, a Manchester lawyer representing the state, said Scanlan went into court seeking the protection upon learning NHIT trustees adopted a resolution on April 11 to dissolve the trust.
'We are unpacking all the issues as this has come together so quickly in the last 30 days,' Ferrari said.
NHIT is the smallest of four firms that manage health insurance and/or property and casualty insurance coverage for government entities.
Affected communities include the cities of Berlin, Laconia and Franklin, along with the towns of Amherst, Milford, Wilton and many communities in the Great North Woods region.
The state's risk management law exempts these firms from having to file any reports with the Internal Revenue Service or to be subject to regulation of the Department of Insurance.
Scanlan's bureau was the only government entity charged with ensuring that the pooled risk management companies are financially solvent.
Probe of NHIT goes back 4 years
The state Bureau of Securities Regulation going back to 2021 opened a financial probe into NHIT operations.
The bureau claimed NHIT and two affiliate groups, Albert C. Jones Employee Benefits Inc. and Albert C. Jones2, violated state laws through misuse of public funds and the diversion of surplus owed to the government members of the trust.
Lawyers for NHIT have denied the charges.
An administrative proceeding against NHIT is pending with a hearing on the merits set for December.
Two months ago, Scanlan asked the Legislature to pass legislation (SB 297) to adopt more restrictive 'guardrails' for all pooled risk management programs to ensure they are financially sound.
At that time, Scanlan warned both New Hampshire Interlocal Trust and HealthTrust, the largest pooled risk management program, were in danger of becoming financially insolvent.
'If that bill was in place, NHIT would not be insolvent,' Scanlan said.
The Senate passed it without debate on a voice vote. The House Commerce and Small Business Committee held a public hearing last month and has scheduled a work session on the issue next week.
HealthTrust represents 191 of the state's 234 cities and towns, six of 10 counties, 85 school groups and 74 other units like water, library and fire districts.
HealthTrust officials said Scanlan's actuary drew false conclusions about the program's finances and maintained that it had more than enough assets to be viable.
They maintain Scanlan's bill sets asset levels that are too low to create a healthy climate for the risk pools.
Scanlan released an April 11 statement that alleged HealthTrust on numerous occasions ignored the advice of their own actuaries to raise rates from 2020-23.
Last month, HealthTrust executives announced that they would exit the market should the Senate-passed bill be signed into law.
klandrigan@unionleader.com

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles

Associated Press
09-07-2025
- Associated Press
ZEO ScientifiX Positions for National Growth as Stem Cell Market Opens in Florida
ZEO Launches New Website and Agency Partnerships to Address Expected Biologics Market Demand Following Florida's New Stem Cell Law FORT LAUDERDALE, FL / ACCESS Newswire / July 9, 2025 / ZEO ScientifiX, Inc. ('ZEO' or the 'Company') (OTCQB:ZEOX), a clinical-stage biopharmaceutical company pioneering the development of innovative biological therapeutics, is spearheading an expansion initiative aligned with the implementation of Florida's new SB-1768 stem cell law. With Florida now authorizing the use of non-FDA-approved stem cell therapies that are compliant with the new regulations for the treatment of certain defined conditions, ZEO is seeking to take advantage of the opportunity to set what it believes will be the industry standard through its product platform, new agency partnerships and educational initiatives. The Future of Regenerative Medicine is Now ZEO's turnkey product platform consists of a proprietary suite of ethically sourced biologics, developed and processed in a state-of-the-art FDA-registered, cGMP-compliant facility and physician education initiatives to assist Florida physicians in delivering regenerative care safely and compliantly under the new Florida guidelines. With an inventory of safe, regulatory-compliant biologics, a history of first-class research and competitive pricing, ZEO believes it is uniquely positioned to lead Florida's new era of accessibility and innovation in the biologics market. 'We believe that ZEO is entering into a new chapter of growth and expect additional states to join Florida in recognizing the therapeutic potential of regenerative biologics,' said Ian Bothwell, interim chief executive officer of ZEO ScientifiX. 'We're not just ready for this shift, we've built the product platform, partnerships and scientific roadmap to lead it.' With an expanding product pipeline, physician education initiatives and a strong compliance focus, ZEO is positioning itself as the go-to source for safe, effective and ethically developed regenerative therapies that have been legally approved. ZEO Launches New Website to Reflect Market Evolution In conjunction with the July 1, 2025, effective date of the new Florida legislation, ZEO has unveiled a newly redesigned website at The new platform highlights the Company's commitment to education, compliance and long-term therapeutic innovation - offering streamlined access to clinical data, physician resources and product information. Strategic Agency Partnerships Support National Brand Presence To further support this next phase of growth, ZEO ScientifiX has partnered with two key agencies: ZEO believes that these partnerships will help them amplify their message and elevate their presence across emerging regenerative medicine markets in Florida and other states, when and where applicable. About ZEO ScientifiX, Inc. ZEO ScientifiX, Inc. (OTCQB:ZEOX) is not just committed to maintaining pace with regulatory change - our goal is to set the standard. As a clinical-stage biopharmaceutical company focused on the development of biological therapeutic platforms, we believe that when physicians are educated, patients are better served - and innovation thrives. We are driven by a commitment to advance the frontiers of regenerative medicine and biologic therapeutics, delivering meaningful solutions for patients and providers worldwide. Our proprietary products, including (a) Zofin™, which are derived from perinatal sources and manufactured to retain the naturally occurring extracellular vesicles, proteins and cell secreted nanoparticles, and (b) Patient Pure X™ ('PPX™"), an autologous biologic containing a nanoparticle fraction that is precipitated from a patient's own peripheral blood, are manufactured in an FDA-registered, cGMP-compliant laboratory. To learn more, please visit Forward-Looking Statements Certain statements contained in this press release should be considered forward-looking statements within the meaning of the Securities Act of 1933, as amended (the 'Securities Act'), the Securities Exchange Act of 1934, as amended (the 'Exchange Act'), and the Private Securities Litigation Reform Act of 1995. These forward-looking statements are often identified by the use of forward-looking terminology such as 'will,' 'believes,' 'expects,' 'potential,' or similar expressions, involving known and unknown risks and uncertainties. Although the Company believes that the expectations reflected in these forward-looking statements are reasonable, they do involve assumptions, risks, and uncertainties, and these expectations may prove to be incorrect. No assurances can be given that the Florida Stem Cell Law will be beneficial to the Company or any initiatives related to this new law will increase our revenues and/or the price of our common stock to a level that is attractive to brokerage houses and institutional investors. We remind you that actual results could vary dramatically as a result of known and unknown risks and uncertainties, including but not limited to: potential issues related to our financial condition, competition, the ability to retain key personnel, product safety, efficacy and acceptance, the commercial success of any new products or technologies, success of clinical programs, ability to retain key customers, our inability to expand sales and distribution channels, legislation or regulations affecting our operations, including product pricing, reimbursement or access, the ability to protect our patents and other intellectual property both domestically and internationally, and other known and unknown risks and uncertainties, including the risk factors discussed in the Company's periodic reports that are filed with the SEC and available on the SEC's website ( You are cautioned not to place undue reliance on these forward-looking statements. All forward-looking statements attributable to the Company or persons acting on its behalf are expressly qualified in their entirety by these risk factors. Specific information included in this press release may change over time and may or may not be accurate after the date of the release. ZEO has no intention and specifically disclaims any duty to update the information in this press release. Contact Information Chloe Detrick Plus4 Public Relations [email protected] SOURCE: ZEO ScientifiX, Inc. press release


Business Wire
09-07-2025
- Business Wire
Third Partners Releases Streamlined SB-261 Compliance Strategy for Companies Ahead of California Climate Risk Reporting Deadline
MORRISTOWN, N.J. & MINNEAPOLIS--(BUSINESS WIRE)-- Third Partners, a full-service sustainability management consulting firm, is using AI-powered tools to give companies doing business in California a streamlined option for meeting the requirements of the state's new climate law. California Senate Bill 261 (SB-261) mandates that all U.S. businesses with annual revenues exceeding $500 million publish biannual climate-related financial risk reports. The deadline to post the first report is January 1, 2026. SB-261 requires companies doing business in California to detail their material financial risks and opportunities related to climate change impacting both immediate and long-term financial outcomes. The deadline is January 1, 2026. 'This bill is a critical step toward corporate accountability and transparency around climate change; however, many companies are struggling to internally manage the new assessments, data collection, and reporting mechanisms required by the law,' explained John Haugen, principal and client director for Third Partners. 'Our firm has developed a unique approach using AI tools and processes to help companies quickly meet the law's expectations while also building value for their brands.' SB-261 requires companies to detail their material financial risks and opportunities related to climate change impacting both immediate and long-term financial outcomes. Companies will need to anticipate, measure, and report on all relevant opportunities and vulnerabilities, from legal liabilities contributing to climate change to climate-related property damage and supply chain disruptions. Failure to comply with SB-261 will cost companies up to $50,000 a year in penalties, with potential legal action and reputation damage. As a boutique firm of specialists in sustainability and business operations, Third Partners offers a highly competitive alternative to inflated consulting strategies and generic software products. Third Partners' approach for meeting the requirements of SB-261 is efficient, grounded in the best sustainability practices, and actively managed from start to finish by the firm's principal executives. "Third Partners did a great job on our SB-261 disclosure. As a client, it was an easy project plan for us to follow and their use of technology tools made the process quite efficient and the result exceeded our expectations," according to Janine Musorafite, Chief Compliance Officer at Epic Staffing Group. About Third Partners Third Partners is a full-service sustainability management consulting firm dedicated to empowering organizations to drive business value and enhance their competitive edge. We achieve these results by offering strategic advisory, data management, and tailored solutions that align brand, product, and mission, ensuring companies meet the evolving expectations of buyers, investors, regulators and customers. Our clients include global brands, middle market leaders, and mission-driven startups who aspire to create more valuable and resilient companies.

Associated Press
24-06-2025
- Associated Press
ZEO ScientifiX Launches Physician-Focused Masterclass Ahead of Florida's SB-1768 Law Implementation
FORT LAUDERDALE, FL / ACCESS Newswire / June 24, 2025 / ZEO ScientifiX, Inc. ('ZEO' or the 'Company') (OTCQB:ZEOX), a clinical-stage biopharmaceutical company pioneering the research and development of innovative biological therapeutics, has announced their upcoming ZEO Masterclass - a physician-led initiative designed to educate Florida doctors on one of the most significant regulatory changes in recent healthcare history. The New Frontier in Regenerative Medicine With Florida's SB-1768 law ('Law') set to take effect on July 1, 2025, licensed MDs and DOs will, for the first time in accordance with the terms of the Law, be authorized to offer non-FDA-approved stem cell therapies directly to patients in defined medical indications and only if conducted under strict compliance protocols. This legislative breakthrough introduces transformative potential across multiple specialties, including: While this Law opens clinical and commercial doors to ZEO that, until now, have previously been unavailable unless such products were FDA approved, it also presents a complex and unfamiliar landscape for physicians who will be obligated to comply with the regulations outlined under the Law. That is why ZEO is stepping in to serve as a bridge between this groundbreaking legislation and responsible, compliant medical practice. 'As a company with deep roots in Florida, a strong research foundation and an FDA-registered facility, we are uniquely positioned to be the state's most trusted source for safe, high-quality stem cell products that are within the guidelines of the new law,' said Ian Bothwell, interim chief executive officer of ZEO ScientifiX. 'We're proud to support physicians in their desire to incorporate innovative solutions that meet the highest standards of science, ethics and patient care.' The ZEO Masterclass: Designed for Today's Physician-Pioneers Unlike any other offering in the field, the ZEO Masterclass is a four-hour intensive training created specifically for physicians ready to lead this new era of regenerative medicine. From legal compliance to clinical integration, the curriculum delivers: Attendees will receive direct instruction from leading experts in biologics and compliance - equipping them to implement regenerative therapies responsibly and confidently. Upcoming Event Details ZEO Masterclass on Stem Cells & Exosomes Date: Friday June 27th Time: 9:00 AM - 2:00 PM (Lunch Included) Location: Alvin Sherman Library, 5th Floor Address: 3100 Ray Ferrero Jr Blvd, Davie, FL 33314 Hosted at NOVA Southeastern University, South Florida Physicians ready to lead the future of healthcare can register now at ZEO's website or contact [email protected] for more information. About ZEO ScientifiX, Inc. ZEO is not just keeping pace with regulatory change - we're setting the standard. As a clinical-stage biopharmaceutical company focused on the development of biological therapeutic platforms, we believe that when physicians are educated, patients are better served - and innovation thrives. We are driven by a commitment to advance the frontiers of regenerative medicine and biologic therapeutics, delivering meaningful solutions for patients and providers worldwide. Our proprietary products, including (a) Zofin™, which are derived from perinatal sources and manufactured to retain the naturally occurring extracellular vesicles, proteins and cell secreted nanoparticles and (b) Patient Pure X™ ('PPX™"), an autologous biologic containing a nanoparticle fraction that is precipitated from a patient's own peripheral blood. During November 2024, the Company announced that it was launching the first planned collaborative product with Exotropin; 'ZEO HAIR GROW™ Powered By Exotropin™", a proprietary topical physician formulated hair regrow system. The Company's proprietary products are manufactured in an FDA-registered, cGMP-compliant laboratory. To learn more, please visit Forward-Looking Statements Certain statements contained in this press release should be considered forward-looking statements within the meaning of the Securities Act of 1933, as amended (the 'Securities Act'), the Securities Exchange Act of 1934, as amended (the 'Exchange Act'), and the Private Securities Litigation Reform Act of 1995. These forward-looking statements are often identified by the use of forward-looking terminology such as 'will,' 'believes,' 'expects,' 'potential,' or similar expressions, involving known and unknown risks and uncertainties. Although the Company believes that the expectations reflected in these forward-looking statements are reasonable, they do involve assumptions, risks, and uncertainties, and these expectations may prove to be incorrect. No assurances can be given that the Florida Stem Cell Law will be beneficial to the Company or any initiatives related to this new law will increase the price of our common stock to a level that is attractive to brokerage houses and institutional investors. We remind you that actual results could vary dramatically as a result of known and unknown risks and uncertainties, including but not limited to: potential issues related to our financial condition, competition, the ability to retain key personnel, product safety, efficacy and acceptance, the commercial success of any new products or technologies, success of clinical programs, ability to retain key customers, our inability to expand sales and distribution channels, legislation or regulations affecting our operations, including product pricing, reimbursement or access, the ability to protect our patents and other intellectual property both domestically and internationally, and other known and unknown risks and uncertainties, including the risk factors discussed in the Company's periodic reports that are filed with the SEC and available on the SEC's website ( You are cautioned not to place undue reliance on these forward-looking statements. All forward-looking statements attributable to the Company or persons acting on its behalf are expressly qualified in their entirety by these risk factors. Specific information included in this press release may change over time and may or may not be accurate after the date of the release. ZEO has no intention and specifically disclaims any duty to update the information in this press release. Contact Information Chloe Detrick Plus4 Public Relations [email protected] SOURCE: Zeo ScientifiX, Inc. press release